digraph CerebralToxoplasmosis {
    node [shape=box, style=filled, color=lightblue];

    Start [label="Suspected Cerebral Toxoplasmosis"];
    
    subgraph cluster_diagnosis {
        label="Diagnosis";
        style=filled;
        color=lightgrey;
        
        NeuroDeficits [label="Progressive Neurological Deficits"];
        Imaging [label="Contrast-enhancing Mass Lesion(s) on CT/MRI"];
        TreatmentResponse [label="Successful Response to Treatment within 2 Weeks"];
        
        Diagnosis [label="Diagnosis: Cerebral Toxoplasmosis", shape=ellipse, color=lightgreen];
        
        NeuroDeficits -> Diagnosis [label="Yes"];
        Imaging -> Diagnosis [label="Yes"];
        TreatmentResponse -> Diagnosis [label="Yes"];
    }
    
    subgraph cluster_treatment {
        label="Treatment";
        style=filled;
        color=lightgrey;
        
        PyrimethamineSulfadiazine [label="Pyrimethamine 200 mg load, then 50 mg/day + Sulfadiazine 1 g four times daily (oral)"];
        Alternative1 [label="Trimethroprim/sulfamethoxazol (TMP) 2.5–5 mg/kg (TMP) q.i.d."];
        Alternative2 [label="Pyrimethamine 50 mg/day + Clarithromycin 1 g twice daily"];
        Alternative3 [label="Pyrimethamine 50 mg/day + Azithromycin 600–1800 mg/day"];
        Alternative4 [label="Pyrimethamine 50 mg/day + Dapsone 100 mg/day"];
        Alternative5 [label="Atovaquone 750 mg four times daily (oral)"];
        
        SecondaryProphylaxis [label="Secondary Prophylaxis: Pyrimethamine 50 mg/day + Sulfadiazine 500 mg four times daily or Atovaquone 750 mg four times daily"];
    }
    
    Start -> NeuroDeficits;
    Start -> Imaging;
    Start -> TreatmentResponse;
    Diagnosis -> PyrimethamineSulfadiazine [label="Primary Therapy"];
    Diagnosis -> Alternative1 [label="Alternative Therapy"];
    Diagnosis -> Alternative2 [label="Alternative Therapy"];
    Diagnosis -> Alternative3 [label="Alternative Therapy"];
    Diagnosis -> Alternative4 [label="Alternative Therapy"];
    Diagnosis -> Alternative5 [label="Alternative Therapy"];
    PyrimethamineSulfadiazine -> SecondaryProphylaxis [label="6 weeks"];
    Alternative1 -> SecondaryProphylaxis [label="6 weeks"];
    Alternative2 -> SecondaryProphylaxis [label="6 weeks"];
    Alternative3 -> SecondaryProphylaxis [label="6 weeks"];
    Alternative4 -> SecondaryProphylaxis [label="6 weeks"];
    Alternative5 -> SecondaryProphylaxis [label="6 weeks"];
}
